Thomas Wei Is The Same Analysts At Jefferies That Predicted ACAD Drug Approval on March 25th and Shares Went Up $5.00 on April 11th. I provided link from March 25th Article. This is the same analyst predicting $18 after earnings report.
Article : Acadia shares rise as analyst sees drug approval
Associated Press – Mon, Mar 25, 2013 1:18 PM EDT
Jefferies analyst Thomas Wei says that overall feedback on new data from a study of pimavanserin has been positive. The analyst said Jefferies spoke with 28 neurologists about the drug at a recent conference.
Google to Verify
Lovaza has also been demonstrated to reduce VLDL-cholesterol and non-HDL-cholesterol, and increase HDL-cholesterol. But, it can raise LDL-cholesterol up to 45% Vascepa will undoubtedly become a major competitor for Lovaza. In clinicial trials, Vascepa was shown to lower triglycerides; while Lovaza also lowers the triglyceride concentration, Vascepa also lowers LDL-C; Lovaza does not. Lovaza was approved to treat people with very high triglyceride levels ( 500 mg/dl), Vascepa is also approved for this market; however the company has also demonstrated that the drug can impact levels in people with high triglyceride ( 200 mg/dl and
No FDA decision on NCE, co has not established partnership to market/
Market Watch 5/3/13
FDA letter, earnings disappointment don’t slow down Gilead shares
May 3, 2013, 11:39 AM
By Russ Britt
Investors nevertheless pushed the stock up another 7%, still euphoric over Gilead’s new hepatitis C drug, sofosbuvir, that seems to be coasting through the trial stage. The company on Thursday morning reported highly successful results for sofosbuvir in trials, curing at least 95% of those in various types of tests and 100% in some cases. When it reported earnings after the close, however, the news wasn’t as bright.
The company said in a conference call with analysts that the FDA sent a letter raising concerns about lab records and test procedures at the Foster City facility. Dow Jones quoted Executive Vice President Norbert Bischofberger as calling the FDA letter a “little setback.”